Canbridge FY26 H1 swings to RMB 37.09 million loss; revenue rises 25.6% to RMB 27.9 million

• Canbridge Pharmaceuticals posted a net loss of RMB 37.09 million, swinging from a profit on sharply lower other income and gains.
• Revenue rose 25.6% to RMB 27.94 million, driven by higher sales of Hunterase and Livmarli.
• Other income and gains fell 89.1% to RMB 11.34 million, following a RMB 101.04 million gain from a U.S. lease termination last year.
• Selling and distribution costs climbed 36.3% to RMB 30.91 million, reflecting Gaurunning’s commercialization launch and a shift to a CSO model.
• Adjusted loss under IFRS narrowed to RMB 28.21 million from RMB 37.35 million, excluding share-based payments and lease-related items.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12304717), on August 28, 2026, and is solely responsible for the information contained therein.